India Exchange Filings

NATCO Pharma Q2 FY27 Earnings Presentation

Natco Pharma Ltd reports Q2 FY27 revenue of ₹1,019.4 crore, down 30.3% YoY, and PAT of ₹202.6 crore

  • Revenue rose 28.3% sequentially; EBITDA was ₹310 crore, with a 30.4% margin including other income.
  • PAT and share of associate profit fell 60.9% YoY and 1.9% sequentially; EPS was ₹11.31.
  • Acquired an additional 13.25% stake in Adcock Ingram, taking its holding to 49%; invested a further US$16.7 million in eGenesis.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.